193001-91-1

Usage

Uses

Used in Pharmaceutical Industry:
(2-CHLORO-6-METHOXY-PYRIDIN-4-YL)-METHANOL is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, (2-CHLORO-6-METHOXY-PYRIDIN-4-YL)-METHANOL serves as an intermediate in the production of agrochemicals. Its role in the synthesis of these chemicals helps to improve crop protection and yield, supporting sustainable agriculture practices.
Used in Organic Chemistry Research:
(2-CHLORO-6-METHOXY-PYRIDIN-4-YL)-METHANOL is utilized as a research compound in organic chemistry. Its distinctive structure makes it a valuable tool for studying chemical reactions and mechanisms, furthering the understanding of organic chemistry and its applications.

Upstream product

• 5398-44-7 2,6-dichloropyridine-4-carboxylic acid 
• 42521-10-8 2-chloro-6-methoxyisonicotinic acid methyl ester 

Downstream Products

• 888729-56-4 3-benzyl-10-(hydroxymethyl)-1,2,3,4,5,6-hexahydro-1,5-methanopyrido[1,2-a][1,5]diazocin-8-one 
• 888729-67-7 3-benzyl-10-[(methoxymethoxy)methyl]-1,2,3,4,5,6-hexahydro-1,5-methanopyrido[1,2-a][1,5]diazocin-8-one 
• 888729-65-5 1'-benzyl-5'-hydroxymethyl-6-methoxy-4-[(methoxymethoxy)methyl]-[2,3']bipyridinyl-1'-ium bromide 
• 478946-80-4 4-(bromomethyl)-2-chloro-6-methoxypyridine 
• 478946-79-1 n-propyl 4-(bromomethyl)-6-methoxy-2-pyridinecarboxylate 
• 308357-95-1 n-propyl 4-((1Z)-2-{[(benzyloxy)carbonyl]amino}-3-methoxy-3-oxo-1-propenyl)-6-methoxy-2-pyridinecarboxylate 
• 308357-98-4 (+)-methyl N-(benzyloxycarbonyl)-3-(n-propyloxycarbonyl-6-methoxy-4-pyridinyl)-L-alaninate 
• 478946-88-2 4-((S)-2-Benzyloxycarbonylamino-2-carboxy-ethyl)-6-methoxy-pyridine-2-carboxylic acid 
• 1402738-51-5 2-chloro-6-methoxy-4-(methoxymethyl)pyridine 

Relevant academic research and scientific papers

Discovery of a Class of Potent and Selective Non-competitive Sentrin-Specific Protease 1 Inhibitors

Sentrin-specific proteases (SENPs) are responsible for the maturation of small ubiquitin-like modifiers (SUMOs) and the deconjugation of SUMOs from their substrate proteins. Studies on prostate cancer revealed an overexpression of SENP1, which promotes prostate cancer progression as well as metastasis. Therefore, SENP1 has been identified as a novel drug target against prostate cancer. Herein, we report the discovery and biological evaluation of potent and selective SENP1 inhibitors. A structure-activity relationship (SAR) of the newly identified pyridone scaffold revealed allosteric inhibitors with very attractive in vitro ADMET properties regarding plasma binding and plasma stability for this challenging target. This study also emphasizes the importance of biochemical mode of inhibition studies for de novo designed inhibitors.

PYRROLIDINE-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE 1NHIBITORS, COMPOSITIONS, AND THEIR USE

In its many embodiments, the present invention provides provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and tautomers and stereoisomers thereof, and pharmaceutically acceptable salts of said compounds, said tautomeros and said stereoisomers, where in each of W, Z, R1H, R2, R3, R4, ring A, ring B, m, n, p, and- L1 - is as defined herein. The novel compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related there to. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including Alzheimer?s disease, are also disclosed

Tyrosine kinase inhibitors

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.

Nonproteinogenic amino acids: An efficient asymmetric synthesis of (S)-(-)-acromelobic acid and (S)-(-)-acromelobinic acid

An efficient synthesis of (S)-(-)-acromelobic acid (1) and (S)-(-)-acromelobinic acid (2) is described via asymmetric hydrogenation protocol. Asymmetric hydrogenation of dehydroamino acid derivative 23 using (R,R)-[Rh(DIPAMP)(COD)]BF4 catalyst followed by removal of the protective groups afforded (S)-(-)-acromelobic acid (1) in >98% ee. The key intermediate 23 was prepared from citrazinic acid (8). The dehydroamino acid derivative 33 required for the synthesis of (S)-(-)-2 was prepared from 2,5-lutidine (27), which upon hydrogenation using (S,S)-[Rh(Et-DuPHOS)(COD)]BF4 catalyst afforded (S)-(+)-34 in 93% yield and >96% ee. Removal of protective groups in (S)-(+)-34 afforded (S)-(-)-acromelobinic acid (2) in good overall yield.

An efficient enantioselective synthesis of (S)-(-)-acromelobic acid

(Equation Presented) A highly efficient enantioselective synthesis of (S)-(-)-acromelobic acid (1) was achieved via asymmetric hydrogenation of dehydroamino acid derivative (3) using (R,R)-[Rh(DIPAMP)(COD)]BF4 catalyst followed by removal of protective groups in >98% ee and good over all yield. The key intermediate (3) was prepared from the commercially available citrazinic acid (4) in six steps.